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2 LIPOLYSIS GENERATES PLATELET DYSFUNCTION AFTER IN VIVO 
HEPARIN ADMINISTRATION 
 
ABSTRACT 
Heparin, when administered to patients undergoing operations using 
cardiopulmonary bypass, induces plasma changes that gradually impair 
platelet macroaggregation, but in vitro heparinisation of whole blood does not. 
The plasma changes induced by in vivo heparin continue to progress in whole 
blood ex vivo. Heparin releases several endothelial proteins including 
lipoprotein lipase, hepatic lipase, platelet factor-4 and superoxide dismutase. 
These enzymes, which remain active in plasma ex vivo, may impair platelet 
macroaggregation after in vivo heparinisation and during cardiopulmonary 
bypass. In the current study proteins were added to hirudin-anticoagulated 
blood (200 U ml-1) from healthy volunteers in vitro and whole blood 
impedance aggregometry assessed the platelet macroaggregatory responses 
to ex vivo stimulation with collagen (0.6 µg ml-1). Over a 4 hour period human 
lipoprotein lipase and human hepatic lipase reduced the platelet 
macroaggregatory response from (mean ± 1SD) 17.0 ± 2.3 to 1.6 ± 1.3 and 
1.2 ± 0.6 Ohms respectively (all p<0.01; n=6). Other lipoprotein lipases also 
impaired platelet macroaggregation but platelet factor-4 and superoxide 
dismutase did not. Platelet macroaggregation had an inverse linear correlation 
with plasma non-esterified fatty acid concentrations (r2=0.69; two sided 
p<0.0001; n=8), suggesting that heparin-induced lipolysis inhibits platelet 
macroaggregation. Lipoprotein degradation products may cause this inhibition 
by interfering with eicosanoids and other lipid mediators of metabolism. 
3INTRODUCTION 
Platelet dysfunction is a major contributor to the bleeding diathesis that 
increases transfusion requirements in up to 29% of patients undergoing 
operations using cardiopulmonary bypass [1]. The platelet function defect that 
develops during cardiopulmonary bypass is the inability to form large stable 
aggregates (macroaggregates) [2-4] while the formation of small aggregates 
(microaggregates) is not impaired [2-4]. 
 
While heparin has proaggregatory effects that augment platelet 
microaggregation [5,6], we and others have shown that heparin impairs 
platelet function before the start of extracorporeal circulation [4,7]. It has also 
been shown that while intravenous heparin markedly inhibits platelet 
macroaggregation, this inhibition is not reproduced by in vitro heparinisation of 
whole blood [4,8,9]. Platelet secretion of 5-hydroxytryptamine is similarly 
impaired by heparin in vivo but not in vitro [10]. These contrasting effects of 
heparin in vivo and in vitro suggest possible endothelial involvement in 
heparin-platelet interactions. 
 
In earlier studies we showed that in vivo heparinisation gradually induced 
platelet dysfunction by causing plasma changes [9]; these plasma changes 
continued to develop ex vivo, after heparinisation in vivo [9]. We also 
observed that this action of heparin was not dose related when heparin doses 
of 30 u kg-1 or more were given[9]. When fully developed, the effect almost 
completely abolished platelet macroaggregation [9]. In contrast the plasma 
obtained from blood in which platelets were dysfunctional, after heparinisation 
4in vivo, inhibited platelet macroaggregation in vitro, without delay [9]. These 
observations also support the suggestion of previous workers that the platelet 
defect associated with cardiopulmonary bypass is extrinsic to the platelet [11] 
and suggest that intermediaries may act on plasma components to produce 
inhibitory substances, rather than inhibiting platelets directly. Micro- and 
macroaggregation in blood from unheparinised subjects was not affected by 
delay [12,13]. 
 
Heparin releases several endothelial proteins into the plasma [14], including 
lipoprotein lipase and hepatic lipase. These enzymes continue to hydrolyse 
plasma lipoproteins ex vivo after heparinisation in vivo [15,16]. Several 
products of lipoprotein hydrolysis inhibit platelet macroaggregation; these 
include free fatty acids (with unsaturated free fatty acids having a more 
pronounced effect) [17,18], Apolipoprotein E, [19], HDL [20] and 
lysophospholipids [21]. Other heparin-releasable endothelial proteins include 
platelet factor-4 and superoxide dismutase [14]. We hypothesised that 
heparin-induced lipolysis may cause platelet dysfunction and therefore 
investigated the effect of these proteins on platelet macroaggregation in whole 
blood. 
 
METHODS 
We carried out a series of four in vitro studies. In Study 1, the effects of 
human post-heparin lipases on platelet macroaggregation were studied in 
blood from 6 volunteers. In Study 2, the effects of lipoprotein lipase, extracted 
from bovine milk, on platelet macroaggregation was studied in blood from 12 
5volunteers. In Study 3 the effects of Pseudomonas spp. lipoprotein lipase on 
non-esterified fatty acid concentrations and platelet macroaggregation were 
studied in blood from 8 volunteers, while those of human post-heparin hepatic 
lipase were studied in in blood from 5 volunteers. In Study 4, the effects of 
human platelet factor-4 and of superoxide dismutase of bovine erythrocyte 
origin, on platelet macroaggregation, were studied in blood from 3 volunteers. 
All studies were carried out in accordance with the Declaration of Helsinki 
(1989) of the World Medical Association and with the approval of the Royal 
Infirmary of Glasgow Research Ethics Committee (Project No 97SC001 (896) 
on May 7th 1997). Informed consent was obtained from all participants. 
 
Blood Sampling  
Venous blood was taken, using a 19 G needle, from the antecubital fossa of 
healthy volunteers, who had not taken non-steroidal anti-inflammatory drugs 
or other antiplatelet medication for at least 7 days. Blood was anticoagulated 
with r-hirudin (200 U ml-1) in siliconised glass containers, as previously 
described [13]. In earlier studies we demonstrated that both platelet 
aggregatory responses [12] and existent platelet microaggregates [13] are 
stable under these conditions, for up to 24 hours.  
 
We elected to study platelet aggregation in hirudin-anticoagulated whole 
blood as hirudin maintains normocalcaemia and has no known direct action 
on platelets. Platelet aggregation has classically been studied in citrate-
anticoagulated blood or platelet rich plasma. Chelating agents, such as EDTA 
and citrate, cause hypocalcaemia and therefore may not give a true picture of 
6platelet responses [22,23]. Hypocalcaemia favours thromboxane A2 
production and thromboxane A2-dependent secretion during aggregation 
induced by weak agonists, such as ADP or adrenaline [24]. Hirudin 
specifically inhibits thrombin but has little or no effect on platelet activation 
induced by other agonists, such as ADP and collagen in vitro [25]; hirudin 
does not inhibit in vivo propagation of platelet rich thrombus [26]. For these 
reasons hirudin is suitable as an in vitro anticoagulant for studying platelet 
aggregation [27,28]. We have previously studied platelet dysfunction 
occurring during cardiopulmonary bypass using hirudin anticoagulation [2,4,9]. 
 
Protein Addition  
Four heparin-releasable proteins were studied. Lipoprotein lipase and hepatic 
lipase (for reasons discussed in the introduction), superoxide dismutase 
because of its known enzymatic activity in blood, and platelet factor-4 
because of its known association with the platelet. These proteins were added 
to achieve concentrations similar to those observed previously after in vivo 
heparinisation. The concentrations were: platelet factor-4 50 U ml-1 [29], 
superoxide dismutase 100 U ml-1 [30] and total lipase activity 100 U ml-1 [31]. 
The blood was then placed in a waterbath at 37oC and aliquots were sampled 
at set time points for aggregometry and for non-esterified fatty acid assays.  
 
Impedance aggregometry was performed on 0.5 ml aliquots of blood 
immediately after sampling. For assay of non-esterified fatty acids, in Study 3, 
2.5 µg of paraoxon, a cholinesterase inhibitor that also has non-specific 
inhibitory effects on lipases [16], was added to 1 ml of the blood immediately 
7after sampling. These samples were then centrifuged at 3000 rpm and 4 oC 
for 15 minutes, and the supernatant plasma stored at -70 oC. The samples 
were analysed in bulk at the end of the studies. 
 
Protein Sources 
Human hepatic and lipoprotein lipases were extracted from post-heparin 
plasma, as described below. Superoxide dismutase and lipoprotein lipase 
enzymes, the former of bovine erythrocyte origin and the latter extracted from 
bovine milk or from Pseudomonas spp. cultures, were purchased from Sigma-
Aldrich Company Ltd., Poole, UK. Human platelet factor 4 was kindly donated 
by the National Institute for Biological Standards and Control, London, UK. 
Our preliminary studies showed that the TRIS buffers, hypertonic saline and 
ammonium sulphate, that the bovine and human enzymes were preserved in, 
impaired platelet macroaggregation in some individuals. We therefore 
dialysed these enzymes against normal saline before adding them to blood. 
 
Post-Heparin Lipase Extraction 
Patients 
Supplies of human post-heparin hepatic lipase and lipoprotein lipase for 
laboratory use were not commercially available, therefore 2 patients 
undergoing elective coronary artery bypass grafting using cardiopulmonary 
bypass were recruited for extraction of post-heparin lipases. Informed consent 
was obtained from these patients. Platelet function was not studied in these 
patients, their heparinised blood was solely used as a source of lipolytic 
enzymes. These patients were not on aspirin, other non-steroidal anti-
8inflammatory drugs, platelet suppressants, steroids, warfarin, intravenous 
nitrates or heparin. Anaesthetic premedication was with temazepam, and 
induction by propofol. Anaesthesia was maintained with propofol infusion and 
opiates.  Heparinisation was with porcine heparin (Leo Laboratories, 
Risborough, UK; 300 U kg-1) given through a central venous cannula just 
before cannulation of the aorta. 50 ml of blood were sampled 10 minutes after 
heparinisation but before the start of extracorporeal circulation. 
 
Lipase Extraction 
Hepatic and lipoprotein lipases were extracted by a stepwise elution through a 
heparin sepharose column as previously described [32]. Briefly post-heparin 
blood was anticoagulated with r-hirudin 200 U ml-1 and placed on ice 
immediately after sampling. The separation process was carried out in 
refrigerated room at 4 oC. Half the heparin content, as estimated by a 
protamine titration, using the Hepcon® system (Medtronic Ltd, Watford, UK), 
was neutralised ex vivo with protamine. This neutralisation reduced the 
heparin concentration to levels closer to those in the original description of 
this extraction procedure [32], as the heparin in solution may compete with 
that in the column for binding of the lipases and reduce the efficiency of 
extraction. Plasma was separated after centrifugation at 3000 rpm for 15 
minutes. 
 
Heparin sepharose columns were equilibrated with 5 mM Sodium barbital, pH 
7.4 containing 0.15 M of sodium chloride. Aliquots of 4 ml post-heparin 
plasma were diluted 1:1 with 5 mM sodium barbital buffer, pH 7.4, containing 
90.45 M sodium chloride. The separation columns were loaded with 8 ml of 
diluted plasma. Elution through the columns was by washing with 8 ml 
fractions. The first fraction was eluted with 5 mM sodium barbital, pH 7.4 
containing 0.3 M sodium chloride, the next two with 5 mM sodium barbital at 
pH7.4 with 0.72 M sodium chloride, and the final two with 5 mM sodium 
barbital at pH7.4 with 1.5 M sodium chloride. 
 
The fractions were then dialysed against 3.8 M ammonium sulphate and then 
against 0.1 M phosphate buffer, pH 7.4. This method of extraction has a high 
yield of hepatic lipase in Fraction 3 and lipoprotein lipase in Fraction 5 [32].  
 
Impedance Aggregometry in Whole Blood 
An impedance aggregometer (Chronolog 500-VS, Chronolog Corporation, 
Havertown, PA, USA) measured electrical impedance changes in whole 
blood. Aliquots of 500 µl of whole blood were diluted with the same volume of 
saline (0.9%) in plastic cuvettes and equilibrated at 37 oC before 
measurement. The macroaggregatory response to 0.6 µg collagen (Hormon 
Chemie, Munich, Germany) was read as the scale deflection in centimetres at 
5 minutes. The aggregometer was calibrated according to the manufacturer's 
instructions so that a 20 Ohm change in electrical impedance would give a 
deflection of 14 cm, giving a conversion factor of 1.43 Ohms per centimetre. 
 
Collagen was chosen as the in vitro agonist, for aggregometry, because it is 
the principle agonist the platelet encounters in damaged vessel walls during 
primary hemostasis. Later, during secondary hemostasis, thrombin is also an 
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important platelet agonist. Furthermore platelet macroaggregation in response 
to low concentrations of collagen is largely the result of platelet secretion of 
thromboxane A2, and platelet release of ADP and serotonin. [33,34]; the 
involvement of these three other important endogenous platelet agonists 
makes the study of responses to low-dose collagen stimulation in vitro a 
useful global means of assessing platelet responses to physiologically 
relevant stimulation [2,4,9,12,34]. High concentrations of collagen can induce 
a full platelet aggregatory response independently of this autocrine positive 
feedback, however this may be the result of excessive and therefore probably 
non-physiological stimulation. To ensure that stimulation remained within a 
physiological range a collagen concentration of 0.6 µg ml-1 was used; we had 
previously determined that this was just below the minimum concentration that 
elicited a maximal macroaggregatory response [4].  
 
Non-Esterified Fatty Acid Assays 
Non-esterified fatty acid levels were serially determined as a measure of 
lipase enzyme activity. As most enzyme assays use the rate of release of 
breakdown products, under specific conditions, to generate an index of 
enzyme activity, the titres of these breakdown products may more accurately 
reflect enzyme activity. These assays were performed using NEFA C® test kits 
marketed by Wako Chemicals GMBH, Neuss, Germany. Briefly, this is a two 
reaction assay, performed on 96 well microtitre plates. The first reaction is the 
acylation of coenzyme A (CoA) by fatty acids in the presence of acyl-CoA 
synthetase. This was achieved by incubating 5 µl of plasma with 100 µl of 
Reagent A, which contains acyl-CoA synthetase, ascorbate oxidase, CoA, 
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ATP and 4-aminoantipyrine. In the second reaction acyl-CoA is oxidised by 
acyl-CoA oxidase to produce hydrogen peroxide, which in the presence of 
peroxidase causes oxidative condensation of 3-methyl-N-ethyl-(B-hydroxy-
ethyl)-aniline with 4-aminoantipyrine to form a purple pigment. This was 
effected by, adding 200 µl of Colour Reagent B to the wells; this reagent 
contains acetyl-CoA oxidase and peroxidase. The optical density of the 
resultant solution was then read at 550 nm using a Dynatech MR 5000 
platelet reader (Dynatech Corporation, Burlington, MA. USA). The non-
esterified fatty acid concentrations were read directly from a calibration curve 
that was prepared using the standards that were supplied with the kit. 
 
Materials 
Heparin Sepharose CL-6B, purchased from Amersham Pharmacia Biotech 
AB, Uppsala, Sweden. Sodium barbital, Hydrochloric acid, and Ammonium 
sulphate, all purchased from BDH Laboratory Supplies, Poole, UK. Sodium di-
hydrogen phosphate, Formachem (Research International) Ltd., Strathaven, 
UK. Di-sodium hydrogen phosphate, Fissons Scientific Equipment, 
Loughbrough, UK. Dialysis tubing, pore size 12 000-14 000 Daltons, Medicell 
International Ltd., London, UK. Paraoxon, Sigma-Aldrich Company Ltd., Poole, 
UK. 
 
Statistical Analysis 
Data are expressed as means ± 1 standard deviation. Comparisons were 
made using two level analyses of variance (anovar) with Bonferroni correction 
for multiple comparisons. Analyses were performed using Arcus Quickstat 
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Biomedical software (Addison Wesley Longman trading as Research 
Solutions, Cambridge, UK). 
 
RESULTS 
Study 1 
Human Post-Heparin Hepatic Lipase  
The human post-heparin hepatic lipase extract reduced the platelet 
macroaggregatory response to collagen 0.6 µg ml-1 from 17.0 ± 2.3 Ohms to 
4.8 ± 3.7 Ohms after 2 hours and to 1.2 ± 0.6 Ohms after 4 hours (p<0.0001 
and p=0.01 respectively; n=6). See Figure 1. 
 
Human Post-Heparin Lipoprotein Lipase  
Human post-heparin lipoprotein lipase extracts appeared to have a different 
timescale from hepatic lipase for reducing the platelet macroaggregatory 
response. The response fell from 17.0 ± 2.3 Ohms to 9.3 ± 5.2 Ohms after 2 
hours and to 1.5 ± 1.3 Ohms after 4 hours (all p<0.0001; n=6). See Figure 1. 
 
Study 2 
Bovine Milk Lipoprotein Lipase 
Lipoprotein lipase from bovine milk reduced the platelet macroaggregatory 
response less markedly than the human enzymes from 17.6 ± 3.1 Ohms to 
12.8 ± 7.3 Ohms after 2 hours and to 5.8 ± 5.3 Ohms after 4 hours (p=0.06 
and p=0.02 respectively; n=12). See Figure 2. The subjects studied appeared 
to comprise two distinct groups; a quick responding group and a slow 
responding group. See Figure 2. In the quick responders the platelet 
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macroaggregatory response fell from 16.4 ± 1.6 Ohms to 7.7 ± 6.6 Ohms over 
the first 2 hours and to 4.3 ± 3.4 Ohms over the next 2 hours (p=0.06 and 
p=0.02 respectively; n=6). However, in the slow responders the platelet 
macroaggregatory response of 18.8 ± 3.8 Ohms was essentially unchanged 
over the first 2 hours but then fell to 7.3 ± 6.7 Ohms over the next 2 hours 
(p=0.3 and p=0.05 respectively; n=6). See Figure 2. 
 
Study 3 
Pseudomonas Spp. Lipoprotein Lipase 
Platelet Macroaggregation 
This bacterial lipoprotein lipase inhibited platelet macroaggregation more 
rapidly than either the human or the bovine isoenzymes, reducing the 
response to 0.6 µg ml-1 collagen from 16.4 ± 3.3 Ohms to 1.3 ± 1.1 Ohms 
within an hour (p<0.0001; n=8). See Figure 3. The bacterial lipoprotein lipase 
which was supplied as a lyophilised powder and therefore did not require 
dialysis, appeared to be the most potent both in inducing lipolysis and 
inhibiting platelets. Dialysing out preservatives may have impaired the activity 
of the other enzymes studied. 
 
Non-Esterified Fatty Acid Release 
Non-esterified fatty acid generation was measured in the samples to which 
the Pseudomonas spp. lipoprotein lipase had been added. The release of 
non-esterified fatty acids was most marked in the first 15 minutes, increasing 
from 0.13 ± 0.33 mmol l-1 to 2.29 ± 0.86 mmol l-1 (p=0.004; n=8). The 
apparent increase over the last 15 minutes, from 3.26 ± 1.04 mmol l-1 to 3.59 
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± 1.04 mmol l-1, failed to reach statistical significance (p=0.06; n=8) 
suggesting that an equilibrium level or maximal generation was approaching. 
See Figure 3. There was a significant inverse linear correlation between the 
non-esterified free fatty acid concentrations and the platelet 
macroaggregatory response (r2=0.69; two sided p<0.0001; n=8). See Figure 
3. 
 
Human hepatic lipase 
The effects of hepatic lipase on non-esterified fatty acid levels and platelet 
macroaggregation were also studied. In this additional group of volunteers 
human hepatic lipase reduced the platelet macroaggregatory response, less 
markedly than in the earlier subjects. The response fell from 13.7 ± 1.2 Ohms 
to 9.2 ± 1.5 Ohms after 2 hours and to 7.6 ± 2.1 Ohms after 4 hours (p=0.06 
and p=0.2 respectively; n=5). See Figure 4. Over the same period the non-
esterified fatty acid levels rose from 0.26 ± 0.08 mmol l-1 to 0.41 ± 0.01 mmol l-
1 and then to 0.53 ± 0.08 mmol l-1 respectively (p=0.08 and p=0.2 respectively; 
n=5). See Figure 4. There was once again a significant inverse linear 
correlation between the non-esterified fatty acid levels and the platelet 
macroaggregatory response (r2=0.81; two sided p=0.03; n=5). See Figure 4. 
 
Study 4 
Platelet Factor-4 and Superoxide Dismutase 
Platelet factor-4 and superoxide dismutase did not affect platelet 
macroaggregation in whole blood from healthy volunteers in vitro, even after 
incubation at 37oC for 3 hours. See Table 1. No synergistic actions of these 
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enzymes that inhibited platelet macroaggregation were detected, even in the 
presence of heparin. See Table 2. 
 
DISCUSSION 
Lipolytic enzymes are released from the endothelium into the plasma, by in 
vivo heparinization. These lipases and similar enzymes, derived from other 
sources, impaired platelet macroaggregation when added to whole blood in 
vitro. This inhibition was similar to that previously observed after in vivo 
heparinisation [9]. Platelet dysfunction correlated strongly with plasma non-
esterified fatty acid levels suggesting that products of plasma lipoprotein 
hydrolysis impaired platelet macroaggregation; the correlation between 
plasma lipase activity and bleeding times previously observed in heparinised 
rabbits [35], supports this hypothesis. The other heparin-releasable proteins 
studied did not affect platelet macroaggregation. 
 
Heparin And Lipid Homeostasis 
Lipoprotein lipase is bound to the endothelial surfaces of arteries and 
capillaries by heparan sulphate. Hepatic lipase is similarly anchored on the 
luminal aspect of liver sinusoids. The location of these enzymes couples 
lipoprotein hydrolysis with the uptake of lipids and apolipoproteins. This helps 
keep plasma concentrations of these lipoprotein breakdown products low, 
favouring further lipoprotein degradation. Dislocation of these enzymes, by 
heparin, uncouples lipoprotein hydrolysis from product uptake, thus increasing 
plasma concentrations of lipoprotein breakdown products, like non-esterified 
fatty acids [31,36]. Accumulation of lipoprotein breakdown products inhibits 
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further lipid breakdown [37]; this inhibition may occur in both the extracellular 
and the intracellular compartments, as small non-polar molecules rapidly 
cross cell membrane lipid bilayers.  
 
Mechanisms By Which Lipolysis May Affect Platelet Aggregation 
Platelet agonists are classified as weak or strong, depending on their ability to 
stimulate platelet secretion and aggregation independently of autocrine 
positive feedback [38]. Thromboxane A2, an eicosanoid (lipid mediator 
derived from arachidonic acid) is a strong platelet agonist that is secreted 
during the autocrine positive feedback induced by weak agonists. The 
alterations in pasma lipids caused by lipolysis may interfere with the 
metabolism of thromboxane and its precursors in several ways: 
 
Arachidonic acid is stored in cell membranes, it is the most abundant fatty 
acid in platelet membranes [38]. Integrin-controlled phospholipases [38] 
mobilise large quantities of arachidonic acid in response to stimulation; this 
occurs in two stages during platelet activation [39]. Arachidonic acid is 
obtained either from dietary sources or synthesised in the liver and 
transported to the tissues that utilise it, as a constituent of plasma 
lipoproteins, only trace quantities of it are found in the free form. Hepatic 
lipase and lipoprotein lipase release arachidonic acid from plasma lipoproteins 
[40]. Arachidonic acid released from plasma lipoproteins during intravascular 
lipolysis will cross cell membranes, thus bypassing the rate limiting (integrin-
controlled) step in eicosanoid synthesis. Lipolysis also increases the 
concentrations of lysophospholipids and non-esterified fatty acids, which will 
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inhibit the hydrolysis of membrane phospholipids, by mechanisms previously 
described [37].  
 
Lipolysis may therefore increase the basal or resting thromboxane production 
while retarding its generation in response to stimuli. Increased thromboxane 
production occurs after in vivo heparin administration [41,42]. Thromboxane 
concentrations correlated with free fatty acid concentrations in one of these 
studies [41]. The previously observed decreased secretion of thromboxane in 
shed blood after heparinisation [7] suggests reduced generation in response 
to stimulation.  
 
Lipolysis may also interfere with platelet macroaggregation because other 
fatty acids normally present in lipoproteins, like eicosapentanoic acid, 
compete with arachidonic acid for enzyme binding sites [43,44]. Eicosanoid 
receptor responses may also be affected by metabolites of arachidonic acid 
[45] and other fatty acids [43,44]. 
 
Cardiopulmonary Bypass 
During cardiopulmonary bypass plasma lipoprotein breakdown product 
concentrations rise markedly after heparinisation and remain elevated 
throughout the period of extracorporeal circulation [46,47]. Haemodilution, 
which occurs during cardiopulmonary bypass, may amplify the effects of 
lipolysis by increasing the amount of lipids that are aqueous (or free) as 
opposed to protein bound. Thus the metabolic effects of heparin-induced 
lipolysis may be more pronounced during cardiopulmonary bypass than they 
18
are in other clinical situations.  
 
Limitations Of Study 
We did not specifically control for the effects of time on platelet 
macroaggregation, however in previous studies we noted that platelet 
macroaggregatory responses were preserved in hirudin-anticoagulated whole 
blood for up to 24 hours [12]. In hirudin-anticoagulated whole blood to which 
heparin was added in vitro these responses were stable for at least three 
hours [9]. The finding in the current study that platelet responses were stable 
over three hours after addition of heparin, platelet factor 4 and superoxide 
dismutase also suggests that deterioration in platelet responses was not 
caused by the delay or the enzyme vehicles.  
 
We did not investigate specific lipoprotein breakdown products for inhibitory 
effects on platelet macroaggregation, however previous studies have already 
shown that several of these products inhibit platelets in a dose dependant 
manner [17,18,19,20]; it is therefore likely that multiple inhibition occurs 
simultaneously. The generation of other lipoprotein breakdown products is 
likely to correlate with that of non-esterified fatty acids and hence their levels 
would also correlate with platelet dysfunction.  
 
We are uncertain as to why platelet macroaggregation deteriorated faster in 
blood from some individuals than others. This may be because they had fewer 
available lipid binding sites on their plasma proteins, or alternatively the faster 
response may be related to the constituents of their lipoproteins.  
19
 
Conclusion 
Heparin releases lipolytic enzymes from the endothelium, these enzymes 
hydrolyse plasma lipoproteins. Lipolysis in whole blood caused platelet 
dysfunction that correlated with the concentration of lipoprotein degradation 
products. This suggests that lipoprotein degradation products may cause the 
platelet dysfunction that occurs in heparinised subjects, including those 
undergoing operations using cardiopulmonary bypass. 
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LEGENDS 
Figure 1 
The Effect Of Human Post-Heparin Lipoprotein Lipase And Hepatic Lipase On 
Whole Blood Impedance Aggregometry In Response To Ex Vivo Stimulation 
With Collagen (0.6µg ml-1) 
 
Mean change in impedance in Ohms; Error bars represent 1 standard error of 
the mean. Filled squares lipoprotein lipase (n = 6): Open squares hepatic 
lipase (n=6). 
 
Figure 2 
The Effect Of Bovine Milk Lipoprotein Lipase (100 u ml-1) On Whole Blood 
Impedance Aggregometry In Response To Ex Vivo Stimulation With Collagen 
(0.6µg ml-1) 
 
Mean impedance change in Ohms; Error bars represent 1 standard error of 
the mean. Open circles represent all subjects (n = 12); Filled squares 
represent the sub-group of slow responders (n = 6): Open squares represent 
the sub-group of fast responders (n=6). 
 
Figure 3 
The Effects Of Pseudomonas Spp. Lipoprotein Lipase (100 u ml-1) On Non-
Esterified Fatty Acid Levels And Impedance Aggregometry In Response To 
Ex Vivo Stimulation With Collagen 0.6 µg mL-1, In Whole Blood 
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Data are mean with error bars representing 1 standard error of the mean 
(n=8). NEFA = non-esterified fatty acids. Filled squares represent NEFA 
levels, Open circles represent impedance changes. *p<0.05: NEFA vs. 
baseline: #p<0.05 Impedance change vs. baseline. For correlation see text. 
 
Figure 4 
The Effects Of Human Hepatic Lipase On Non-Esterified Fatty Acid Levels 
And Impedance Aggregometry In Response To Ex Vivo Stimulation With 
Collagen 0.6 µg mL-1, In Whole Blood 
 
Data are mean with error bars representing 1 standard error of the mean 
(n=5). NEFA = non-esterified fatty acids. Filled squares represent NEFA 
levels, Open circles represent impedance changes. *p<0.05: NEFA vs. 
baseline: #p<0.05 Impedance change vs. baseline. For correlation see text. 
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Table 1. 
 
The Effects Of Heparin, Platelet Factor 4 And Superoxide Dismutase On 
Whole Blood Impedance Aggregometry. 
 
Protein Reading A B C 
Control Immediate 13.1 25.0 20.0 
Heparin 4 u ml-1 Immediate 14.0 25.0 20.0 
 3 hour 13.6 24.3 18.6 
PF4 100 u ml-1 Immediate 16.4 22.0 17.4 
 3 hour 15.6 26.6 16.6 
SOD 100 u ml-1 Immediate 16.6 25.1 26.9 
 3 hour 14.0 24.6 14.9 
 
Macroaggregatory responses to collagen 0.6 µg in whole blood from 3 healthy 
volunteers (A, B and C).  Impedance changes in Ohms. PF4 = Platelet Factor 
4; SOD = Superoxide Dismutase.  
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Table 2. 
 
The Effect Of Different Combinations Of Heparin, Platelet Factor 4 And 
Superoxide Dismutase On Whole Blood Impedance Aggregometry. 
 
Combination Reading A B C 
Control  13.1 25.0 20.0 
H+P Immediate 18.6 23.4 20.3 
 3 hour 14.3 24.3 19.6 
H+S Immediate 17.9 26.6 27.3 
 3 hour 14.3 24.3 19.6 
P+S Immediate 14.9 27.0 19.4 
 3 hour 13.1 26.1 18.3 
H+P+S Immediate 17.1 26.0 24.6 
 3 hour 12.9 25.4 21.4 
 
 
Platelet macroaggregation in response to stimulation with ex vivo collagen 0.6 
µg ml-1, in whole blood from 3 healthy volunteers.  Impedance changes in 
Ohms. H =Heparin 4 u ml-1; PF4 = Platelet Factor-4 100 u ml-1; SOD = 
Superoxide Dismutase 100 u ml-1. 
 
